Loading…
Iovance Biotherapeutics, Inc. is projected to rise to $4.86 by 2027, a +4% move from its current price of $4.69. IOVA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $4.49 | $4.69 | $4.91 | +0.07% |
| Aug 2 | $4.41 | $4.70 | $5.00 | +0.13% |
| Aug 3 | $4.35 | $4.70 | $5.07 | +0.20% |
| Aug 4 | $4.30 | $4.70 | $5.14 | +0.27% |
| Aug 5 | $4.26 | $4.71 | $5.20 | +0.34% |
| Aug 6 | $4.22 | $4.71 | $5.25 | +0.40% |
| Aug 7 | $4.19 | $4.71 | $5.30 | +0.47% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.19 | $4.71 | $5.30 | +0.47% |
| Week 2 | $4.01 | $4.73 | $5.59 | +0.94% |
| Week 3 | $3.88 | $4.76 | $5.83 | +1.42% |
| Week 4 | $3.78 | $4.78 | $6.04 | +1.90% |
| Week 5 | $3.69 | $4.80 | $6.24 | +2.37% |
| Week 6 | $3.62 | $4.82 | $6.43 | +2.86% |
| Week 7 | $3.55 | $4.85 | $6.61 | +3.34% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes cell therapies using autologous tumor infiltrating lymphocytes for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen.
The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc.
in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
IOVA is the stock ticker for Iovance Biotherapeutics, Inc., a Healthcare company.
Current price is $4.56 and the market cap is $2.04B. It is ranked 2028 by market capitalization in its universe.
A major floor 33.4% below — a decisive break under it would weaken the trend.
The nearest floor, 16.6% below — buyers have tended to step in here.
The nearest ceiling, 16.8% above — a clean break opens room to run.
A major ceiling 33.5% above — clearing it would confirm fresh momentum.
Key IOVA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IOVA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.77 | Sell | $4.75 | Sell |
| MA 10 | $4.96 | Sell | $4.78 | Sell |
| MA 20 | $4.64 | Buy | $4.66 | Buy |
| MA 50 | $4.28 | Buy | $4.34 | Buy |
| MA 100 | $4.00 | Buy | $3.99 | Buy |
| MA 200 | $3.29 | Buy | $3.71 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.54 | Neutral |
| Stoch RSI (14) | 28.12 | Neutral |
| CCI (20) | 10.17 | Neutral |
| Williams %R (14) | -50.97 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | 19.34 | Buy |
| Bollinger %B (20,2) | 0.53 | Neutral |
| Stochastic %K (14) | 49.03 | Neutral |
| TRIX (15) | 0.74 | Buy |
| Awesome (5,34) | 0.36 | Buy |
| Ultimate (7,14,28) | 31.75 | Neutral |
| Momentum (10) | 0.03 | Buy |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 4.55 | Buy |
| ADX (14) | 14.25 | Neutral |
| ATR (14) | 0.18 | Info |
The 30-day technical picture is bullish overall. RSI14 is 50, indicating neutral momentum within a bullish sentiment context. The SMA50 is $4.25 and the SMA200 is $3.28, suggesting a constructive setup against a rising longer-term baseline.
Support sits at $3.82 and resistance at $5.48, with the 30-day price range from $3.38 to $6.15. The current price of $4.56 sits near the middle of this range and above the nearby moving-average anchor points.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.22 | $4.69 | $6.52 | 0% | Neutral | |
| $3.66 | $4.86 | $6.95 | +4% | Neutral | |
| $3.76 | $5.26 | $7.94 | +12% | Neutral | |
| $4.21 | $6.13 | $9.67 | +31% | Bullish | |
| $4.15 | $6.27 | $10.25 | +34% | Bullish | |
| $5.62 | $8.78 | $14.80 | +87% | Bullish | |
| $6.53 | $10.54 | $18.27 | +125% | Bullish | |
| $5.88 | $9.79 | $17.38 | +109% | Bullish | |
| $6.05 | $10.38 | $18.84 | +121% | Bullish | |
| $5.91 | $10.43 | $19.33 | +122% | Bullish | |
| $8.94 | $18.08 | $36.49 | +286% | Bullish | |
| $18.66 | $41.46 | $94.39 | +784% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.22 | $4.69 | $5.50 | +0.00% |
| August 2026 | $4.20 | $5.00 | $6.13 | +6.59% |
| September 2026 | $4.13 | $4.99 | $6.25 | -0.27% |
| October 2026 | $3.97 | $4.84 | $6.16 | -2.93% |
| November 2026 | $4.01 | $4.94 | $6.37 | +2.00% |
| December 2026 | $4.02 | $4.99 | $6.52 | +1.09% |
Click any year to see its month-by-month IOVA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IOVA price prediction for 2026 points to an average of $4.69 (low $2.22, high $6.52) — a potential gain of 0% on today's $4.69. Price action looks broadly range-bound.
In 2027, IOVA is projected to trade between $3.66 and $6.95, averaging $4.86 — a potential gain of +4% from today's $4.69. That is up +4% on the projected 2026 average. A consolidation phase looks the most probable path here.
Iovance Biotherapeutics, Inc.'s 2028 outlook centres on $5.26, within a $3.76 to $7.94 range. That is up +8% on the projected 2027 average. That marks a +12% change versus current levels. Price action looks broadly range-bound.
By 2029, IOVA could reach as high as $9.67, with a base case around $6.13 and support toward $4.21 — roughly +31% from $4.69. Buyers look set to stay in control over this stretch.
Expect IOVA to range from $4.15 to $10.25 through 2030. The $6.27 average target implies a +34% move from current prices. That is up +2% on the projected 2029 average. Momentum favours further upside here.
The IOVA price prediction for 2031 points to an average of $8.78 (low $5.62, high $14.80) — a potential gain of +87% on today's $4.69. Buyers look set to stay in control over this stretch.
In 2032, IOVA is projected to trade between $6.53 and $18.27, averaging $10.54 — a potential gain of +125% from today's $4.69. That is up +20% on the projected 2031 average. Momentum favours further upside here.
Iovance Biotherapeutics, Inc.'s 2033 outlook centres on $9.79, within a $5.88 to $17.38 range. That is -7% versus the projected 2032 average. That marks a +109% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, IOVA could reach as high as $18.84, with a base case around $10.38 and support toward $6.05 — roughly +121% from $4.69. Momentum favours further upside here.
Expect IOVA to range from $5.91 to $19.33 through 2035. The $10.43 average target implies a +122% move from current prices. That is up +1% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The IOVA price prediction for 2040 points to an average of $18.08 (low $8.94, high $36.49) — a potential gain of +286% on today's $4.69. Momentum favours further upside here.
In 2050, IOVA is projected to trade between $18.66 and $94.39, averaging $41.46 — a potential gain of +784% from today's $4.69. That is up +129% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IOVA today (≈ 213.219616 IOVA) could be worth
$8,840.65
+$7,840.65 (+784%) by 2050 · US Dollar
Based on the average projected IOVA price of $41.46 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IOVAwould be worth at today's price.
$1,000 invested in IOVA on Jul 30, 2025 (≈ 374.531825 IOVA) would be worth
$1,756.55
+$756.55 (+75.7%) today · 1.76× · US Dollar
Based on a IOVA entry price of $2.67 vs. today's $4.69.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.13 | $914.23 | -8.6% |
| 1 month ago | $4.16 | $1,127.4 | +12.7% |
| 3 months ago | $3.4 | $1,379.41 | +37.9% |
| 6 months ago | $2.55 | $1,839.22 | +83.9% |
| 1 year ago | $2.67 | $1,756.55 | +75.7% |
| All time (5.0y) ago | $22.49 | $208.54 | -79.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IOVA forecast.
Our base-case forecast reaches $9.40 around 2032.
Implied market cap at $9.40: $4.2B
The multi-year forecast shows a path of gradual improvement with meaningful upside in later years. In 2026 the average price is projected to be $4.56 with a min of $2.22 and a max of $6.33, and a neutral sentiment. By 2027 the average price is $4.64 with a max of $6.66 and an ROI of 1.8%, remaining neutral.
In 2028 the average price rises to $4.96 (max $7.54, min $3.54) with an ROI of 8.9% and a neutral stance.
For 2029 the avg price is $5.69 and the max is $9.04, with an ROI of 24.8% and a bullish sentiment. The 2030 projection shows an average of $5.69 with a max of $9.36, ROI 24.7% and bullish sentiment. Looking further out, 2031 is $8.01 (max $13.59), 2032 is $9.62 (max $16.79), and 2033 is $8.85 (max $15.83), all with bullish sentiment and double-digit upside potential.
The longer-horizon forecast extends strong upside to 2040 with an average of $15.90 and a max of $32.39 (ROI 248.7%), and to 2050 with an average of $35.53 and a max of $81.71 (ROI 679.1%), both with bullish sentiment. These are estimates and not guarantees, reflecting shares projected price paths and investor expectations across multiple years.
Tap a question to reveal the answer.
Avg price $5.69; min $3.74; max $9.36; ROI 24.7%; sentiment BULLISH.
Forecasts show neutral sentiment in 2026; then neutral to bullish through 2028, with pronounced upside from 2029 onward. Avg prices rise to $5.69 by 2030 and continue higher to $8.01 by 2031 and beyond, with notable 2040 ($15.90) and 2050 ($35.53) endpoints and double-digit to high double-digit ROIs.
Yes. The forecast for 2032 lists a max of $16.79 with an average of $9.62 and a bullish outlook.
Sentiment: BULLISH. RSI14: 50. SMA50: $4.25. SMA200: $3.28. Support: $3.82. Resistance: $5.48. 30-day range: $3.38 to $6.15.
Current price: $4.56. Market cap: $2.04B. Rank: 2028.
Iovance Biotherapeutics, Inc. Community Discussion
0Share your Iovance Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.